Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Development programme

SOUL — oral semaglutide cardiovascular outcomes

A cardiovascular outcome trial of oral semaglutide in type 2 diabetes with established cardiovascular or chronic kidney disease.

Sponsor class: Manufacturer-sponsored. First record: 2019.

Filter by text

Phase

Status

Showing 0 records on this page

Records in this programme

5 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
SOUL	Semaglutide, oral	Phase 3	Reported	Event-driven cardiovascular outcome trial	9,650	2025	Moderate
SOUL-DDIprogramme record	Semaglutide, oral	Phase 1	Reported	Randomised crossover	—	2025	Very low
SOUL-HEPATIC-IMPprogramme record	Semaglutide, oral	Phase 1	Reported	Phase 1 ascending dose	—	2025	Very low
SOUL-PKprogramme record	Semaglutide, oral	Phase 1	Reported	Phase 1 ascending dose	—	2025	Very low
SOUL-RENAL-IMPprogramme record	Semaglutide, oral	Phase 1	Reported	Phase 1 ascending dose	—	2025	Very low

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.